| Annual · values | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -11.22 M USD | -10.18 M USD | -7.36 M USD | -8.35 M USD |
| Depreciation & Amortization | 138069 USD | 131188 USD | 129653 USD | 125885 USD |
| Stock-Based Compensation | 62744 USD | 245053 USD | 151505 USD | 184465 USD |
| Capital Expenditures | 24213 USD | 8569 USD | 26544 USD | 33101 USD |
| Cash Flow from Investing | -182909 USD | -379246 USD | -318259 USD | -336761 USD |
| Cash Flow from Financing | 8.92 M USD | 13.32 M USD | 5.98 M USD | 4.13 M USD |
| Dividends Paid | — | — | — | — |
| Stock Buybacks | — | — | — | — |
| Free Cash Flow | -11.25 M USD | -10.19 M USD | -7.39 M USD | -8.38 M USD |
Azitra Inc. is a clinical-stage biotechnology company that focuses on harnessing the therapeutic potential of the human microbiome. The company is dedicated to developing microbiome-based treatments to address dermatological conditions and improve skin health. Azitra leverages its proprietary platform to design therapies that utilize commensal microbiota, which are the naturally occurring bacteria on human skin, for combating various skin diseases. By targeting skin-associated microbiomes, Azitra aims to create safe and effective treatment options for conditions that may not respond well to conventional treatments. Its innovative approach positions Azitra in the emerging field of microbiome therapy, impacting healthcare and dermatology industries. With its specialized focus, Azitra plays a significant role in advancing biotechnology innovations and contributing to the evolving narrative of precision medicine and personalized healthcare.